Elevance Health reaffirmed its full-year 2026 earnings guidance during investor meetings, projecting at least $20.10 per diluted share including approximately $6.90 of net unfavorable items, or adjusted shareholders’ earnings of at least $27.00 per diluted share excluding those items. The company also maintained its benefit expense ratio forecast for 2026 at 90.2%, plus or minus 50 basis points. Elevance Health operates in the managed healthcare and insurance industry.

Elevance Health, Inc. issued a press release on July 15, 2026, reporting its financial results for the quarter ended June 30, 2026. Elevance Health, Inc. is a healthcare company providing various insurance and health services.

Elevance Health, Inc. reaffirmed its full year 2026 shareholders' earnings guidance of at least $19.85 per diluted share, which includes approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the company expects adjusted shareholders' earnings to be at least $26.75 per diluted share. Additionally, the company reaffirmed its full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. Elevance Health, Inc. is a healthcare company that provides health insurance and pharmacy services.

Elevance Health, Inc. held its annual meeting of shareholders on May 13, 2026, resulting in the election of three directors and the approval of executive compensation and the appointment of Ernst & Young LLP. A shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan political groups was defeated, receiving 15,587,160 votes in favor and 162,924,290 against.

Elevance Health, Inc. issued a press release on April 22, 2026, reporting its financial results for the quarter ended March 31, 2026. The filing serves as the formal announcement of the company's quarterly financial performance.

Elevance Health reaffirmed its 2026 full-year guidance, projecting adjusted shareholders' earnings of at least $25.50 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points. This guidance incorporates the potential impact of intermediate sanctions from CMS regarding the company's Medicare Advantage-Prescription Drug plans.